| 產品編號 | bs-0699R-Gold |
| 英文名稱 | Rabbit Anti-SLC33A1/Gold Conjugated antibody |
| 中文名稱 | 膠體金標記的乙酰輔酶A轉運蛋白1抗體 |
| 別 名 | AT-1; Solute carrier family 33, member 1; SLC33A1; ACATN; Acetyl CoA transporter; Acetyl Coenzyme A transporter; AT 1; AT1; Human Angiotensin II Type 1 Receptor; Solute carrier family 33 (acetyl CoA transporter) member 1; Solute carrier family 33 member 1; spastic paraplegia 42 (autosomal dominant); SPG42; ACATN_HUMAN; Acetyl coenzyme A transporter 1; Acetyl-CoA transporter 1; Acetyl-coenzyme A transporter 1; Slc33a1; Solute carrier family 33 (acetyl CoA transporter) member 1. |
| 規格價格 | 100ul/2980元 購買 大包裝/詢價 |
| 說 明 書 | 100ul（10nm 15nm 35nm） |
| 研究領域 | 細胞生物 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應 | (predicted: Human, Mouse, Rat, ) |
| 產品應用 | IEM=1:20-200 ICA=1:20-200 ChIP=1:20-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 61kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 0.4mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human SLC33A1 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲 存 液 | 0.02M TBS(pH8.2) with 1% BSA, 0.03% Proclin300. |
| 保存條件 | Store at 2-8 oC for 3-6 months. Avoid repeated freeze/thaw cycles. |
| 產品介紹 |
background: Acetyl-coenzyme A transportor 1 is required for the formation of O-acetylated (Ac) gangliosides. It is predicted to contain 6 to 10 transmembrane domains, and a leucine zipper motif in transmembrane domain III. Studies indicate that the protein is localized to the cytoplasm. Function: Probable acetyl-CoA transporter necessary for O-acetylation of gangliosides. Subcellular Location: Endoplasmic reticulum membrane; Multi-pass membrane protein (Probable). Tissue Specificity: Ubiquitous. Detected in heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas. With strongest signals in pancreas. DISEASE: Defects in SLC33A1 are the cause of spastic paraplegia autosomal dominant type 42 (SPG42) [MIM:612539]. Spastic paraplegia is a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body Similarity: Belongs to the SLC33A transporter family. Database links: Entrez Gene: 9197 Human Omim: 603690 Human SwissProt: O00400 Human Unigene: 478031 Human Unigene: 209601 Rat Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| 1、抗體溶解方法 | |
| 2、抗體修復方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關于肽鏈的設計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
